Current prognostic systems for myelodysplastic syndromes (MDS) are based on clinical, pathologic, and laboratory indicators. The objective of the current study was to develop a new patient-centered prognostic index for patients with advanced MDS by including self-reported fatigue severity into a well-established clinical risk classification: the International Prognostic Scoring System (IPSS).
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes / Efficace, Fabio; Cottone, Francesco; Abel, Gregory; Niscola, Pasquale; Gaidano, Gianluca; Bonnetain, Franck; Anota, Amelie; Caocci, Giovanni; Cronin, Angel; Fianchi, Luana; Breccia, Massimo; Stauder, Reinhard; Platzbecker, Uwe; Palumbo, Giuseppe A; Luppi, Mario; Invernizzi, Rosangela; Bergamaschi, Micaela; Borin, Lorenza; Di Tucci, Anna Angela; Zhang, Huiyong; Sprangers, Mirjam; Vignetti, Marco; Mandelli, Franco. - In: CANCER. - ISSN 0008-543X. - 124:6(2018), pp. 1251-1259. [10.1002/cncr.31193]
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes
Luppi, Mario;
2018
Abstract
Current prognostic systems for myelodysplastic syndromes (MDS) are based on clinical, pathologic, and laboratory indicators. The objective of the current study was to develop a new patient-centered prognostic index for patients with advanced MDS by including self-reported fatigue severity into a well-established clinical risk classification: the International Prognostic Scoring System (IPSS).
| File | Dimensione | Formato | |
|---|---|---|---|
|
Efficace_et_al-2018-Cancer.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
300.75 kB
Formato
Adobe PDF
|
300.75 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
